Company: BBVXF
Filing Date: 2025-02-14
Form Type: 6-K
Source: 0001193125-25-027343
Chunk: 85

Company: BANCO BILBAO VIZCAYA ARGENTARIA, S.A.
Filing Date: 2025-02-14
Form: 6-K
Chunk 85
---
 of Directors of BBVA 70 For the executive directors: • The amounts included in the cells “Financial instruments at the beginning of 2024” and “Financial instruments at the end of 2024” correspond to the number of shares awarded and not yet vested at the beginning and end of 2024, respectively. • The amounts included in the cell “Financial instruments awarded during 2024” correspond to the total shares and instruments awarded under the 2024 AVR, although the portion corresponding to the 2024 LTI, amounting to 119,709 shares in the case of the Chair and 89,529 shares in the case of the Chief Executive Offi cer, is conditional on the outcome of the Long-Term Indicators, which will determine the fi nal amount of the LTI, both in cash and in BBVA shares. • The amounts included in the cell “Financial instruments vested during the year” correspond to:—Short-term variable remuneration: Upfront Portion of the 2024 AVR in shares, to be delivered in 2025.—Long-term variable remuneration: Deferred Portion of the Annual Variable Remuneration from previous fi nancial years, in shares, to be delivered in 2025:—fi rst payment of the Deferred Portion of the 2023 AVR (17.9% of the 2023 DAVR, assuming the maximum achievement level scenario of the 2023 LTI: 150% of Target LTI);—second payment of the Deferred Portion of the 2022 AVR (20% of the 2022 DAVR);—third payment of the Deferred Portion of the 2021 AVR (20% of the 2021 DAVR); and—third and fi nal payment of the Deferred Portion of the 2019 AVR (20% of the 2019 DAVR). Given that, as of the date of drafting of this Report, these shares have not been delivered to their benefi ciaries, for the purpose of calculating their cash value, the same average price as that used to calculate the component in shares of the 2024 AVR has been used. Thus, the average closing price of the BBVA share for the trading sessions running from December 15, 2024 to January 15, 2025 has been taken as a reference, which was €9.67 per share. The price initially used to determine the number of shares corresponding to the Deferred Portion of the